← Back to Search

Other

Active dose for Atopic Dermatitis

Phase 2

Waitlist Available

Research Sponsored by Hangzhou Yirui Pharmaceutical Technology Co., Ltd

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day1-day50

Awards & highlights

Study Summary

"This trial will test a new ointment called YR001 on adults with mild to moderate eczema to see if it is safe and how well the body absorbs it."

Who is the study for?

Adults with mild to moderate atopic dermatitis, commonly known as eczema, can participate in this trial. Specific eligibility criteria are not provided but typically include age range and health status requirements.Check my eligibility

What is being tested?

The trial is testing YR001 ointment's safety, how well it's tolerated by patients, its absorption into the body (pharmacokinetics), and effectiveness in treating atopic dermatitis symptoms.See study design

What are the potential side effects?

While specific side effects of YR001 ointment aren't listed here, common side effects for topical treatments may include skin irritation, redness, itching or burning sensation at the application site.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day1-day50

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day1-day50

This trial's timeline: 3 weeks for screening, Varies for treatment, and day1-day50 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

The primary endpoint will be safety. Specifically, the primary endpoint will be the incidence of treatment-related AEs (TRAEs) through Day 50.

Secondary outcome measures

Efficacy of YR001 Ointment

all treatment-emergents AEs

Trial Design

2Treatment groups

Experimental Treatment

Group I: Placebo doseExperimental Treatment2 Interventions

The intervention is Placebo on a range of body surface area for multiple topical administration

Group II: Active doseExperimental Treatment1 Intervention

The intervention is YR001 ointment on a range of body surface area for multiple topical administration

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Hangzhou Yirui Pharmaceutical Technology Co., LtdLead Sponsor

1 Previous Clinical Trials

54 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are new participants currently being accepted for this research study?

"Per data from clinicaltrials.gov, the current trial is not seeking participants at this time. Originally posted on June 1st, 2024, and last updated on March 6th, 2024. Although inactive now, there are currently 247 other trials actively seeking eligible candidates."

Answered by AI

Has the Active dose been officially sanctioned by the FDA?

"Our team at Power rates the safety of Active dose as a 2 on our scale from 1 to 3. As this is a Phase 2 trial, there exists some data confirming its safety but not yet any supporting efficacy."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis

2024. "Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06309355.

All > Atopic Dermatitis